Literature DB >> 3346624

Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants.

G H Lowell1, L F Smith, R C Seid, W D Zollinger.   

Abstract

Addition of either a lauroyl or a pentapeptide (FLLAV) hydrophobic foot to the NH2 terminus of a small, synthetic peptide allowed the peptide to hydrophobically complex to meningococcal outer membrane protein proteosomes by simple dialysis. Both conventional and LPS-hyporesponsive mice immunized with these complexes without any adjuvants developed high-titered and persistent anti-peptide IgG. Since proteosomes have been safely given to many people and since important antigenic determinants are generally hydrophilic, this system should be widely applicable to the development of peptide vaccines for human use.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3346624      PMCID: PMC2188847          DOI: 10.1084/jem.167.2.658

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  19 in total

1.  Studies of Porins: Spontaneously Transferred from Whole Cells and Reconstituted from Purified Proteins of Neisseria gonorrhoeae and Neisseria meningitidis.

Authors:  E C Lynch; M S Blake; E C Gotschlich; A Mauro
Journal:  Biophys J       Date:  1984-01       Impact factor: 4.033

2.  Effect of carrier on the immunogenic capacity of synthetic cholera vaccine.

Authors:  C O Jacob; R Arnon; M Sela
Journal:  Mol Immunol       Date:  1985-12       Impact factor: 4.407

3.  Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin.

Authors:  H Kawamura; J A Berzofsky
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

4.  A synthetic analogue of Escherichia coli lipoprotein, tripalmitoyl pentapeptide, constitutes a potent immune adjuvant.

Authors:  A Lex; K H Wiesmüller; G Jung; W G Bessler
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

Review 5.  Synthetic vaccines.

Authors:  R Arnon; M Shapira; C O Jacob
Journal:  J Immunol Methods       Date:  1983-07-29       Impact factor: 2.303

6.  Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides.

Authors:  G R Dreesman; Y Sanchez; I Ionescu-Matiu; J T Sparrow; H R Six; D L Peterson; F B Hollinger; J L Melnick
Journal:  Nature       Date:  1982-01-14       Impact factor: 49.962

7.  Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man.

Authors:  W D Zollinger; R E Mandrell; J M Griffiss; P Altieri; S Berman
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

Review 8.  Synthetic peptide immunogens as vaccines.

Authors:  T M Shinnick; J G Sutcliffe; N Green; R A Lerner
Journal:  Annu Rev Microbiol       Date:  1983       Impact factor: 15.500

9.  Synthesis of somatostatin and [D-Trp8]-somatostatin.

Authors:  A M Felix; M H Jimenez; C T Wang; J Meienhofer
Journal:  Int J Pept Protein Res       Date:  1980-04

10.  Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity.

Authors:  L A Chedid; M A Parant; F M Audibert; G J Riveau; F J Parant; E Lederer; J P Choay; P L Lefrancier
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

View more
  14 in total

1.  Induction of cytokine mRNA expression in U937 cells by Salmonella typhimurium porins is regulated by different phosphorylation pathways.

Authors:  Marilena Galdiero; Annalisa Tortora; Nicola Damiano; Mariateresa Vitiello; Anna Longanella; Emilia Galdiero
Journal:  Med Microbiol Immunol       Date:  2005-01       Impact factor: 3.402

Review 2.  Molecular parasitology: progress towards the development of vaccines for malaria, filariasis, and schistosomiasis.

Authors:  S J Cryz
Journal:  Experientia       Date:  1991-02-15

3.  Neisseria meningitidis lipopolysaccharide modulates the specific humoral immune response to neisserial porins but has no effect on porin-induced upregulation of costimulatory ligand B7-2.

Authors:  N Bhasin; Y Ho; L M Wetzler
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge.

Authors:  Delia F Tifrea; Sukumar Pal; Deana N Toussi; Paola Massari; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-08-30       Impact factor: 2.700

5.  Delivery of foreign antigens by engineered outer membrane vesicle vaccines.

Authors:  David J Chen; Nikolaus Osterrieder; Stephan M Metzger; Elizabeth Buckles; Anne M Doody; Matthew P DeLisa; David Putnam
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-27       Impact factor: 11.205

6.  Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines.

Authors:  G H Lowell; C Colleton; D Frost; R W Kaminski; M Hughes; J Hatch; C Hooper; J Estep; L Pitt; M Topper; R E Hunt; W Baker; W B Baze
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

Review 7.  Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activity.

Authors:  Lee M Wetzler
Journal:  Future Microbiol       Date:  2010-05       Impact factor: 3.165

8.  Engineering the cell surface display of cohesins for assembly of cellulosome-inspired enzyme complexes on Lactococcus lactis.

Authors:  Andrew S Wieczorek; Vincent J J Martin
Journal:  Microb Cell Fact       Date:  2010-09-14       Impact factor: 5.328

9.  Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection.

Authors:  C P Mallett; T L Hale; R W Kaminski; T Larsen; N Orr; D Cohen; G H Lowell
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

10.  Characterization and protective effect of a 29 kDa protein isolated from Coxiella burnetii by detergent Empigen BB.

Authors:  M Lukácová; E Gajdosová; L Skultéty; E Kovácová; J Kazár
Journal:  Eur J Epidemiol       Date:  1994-04       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.